Principal Scientist
Boehringer Ingelheim
My name is Emily Werth, PhD and I am a Principal Scientist at Boehringer Ingelheim. I am a group leader in regulated bioanalytical PK assay development for large molecule and new modality programs. I serve as the DMPK project rep on numerous programs in development and my lab focus is on developing and validating immunocapture-based mass spectrometry (IC-LC/MS/MS) methods for pre-clinical and clinical PK. Prior to joining Boehringer Ingelheim, I received my PhD in Analytical Chemistry in 2018 from UNC Chapel Hill before joining Columbia University as a postdoc in the Biological Sciences Department. I have contributed on target engagement biomarker, PK, CQA, and ocular tissue biodistribution work packages for drugs across the development landscape in the BI pipeline.